⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13574813 | 0.74 | — | — | |
| SCHEMBL8830285 | 0.73 | — | — | |
| SCHEMBL12590 | 0.69 | — | — | |
| SCHEMBL22436515 | 0.69 | — | — | |
| SCHEMBL14562570 | 0.69 | — | — | |
| SCHEMBL31595941 | 0.69 | KDM4E (0.36) | — | |
| SCHEMBL15331235 | 0.69 | — | — | |
| SCHEMBL14185284 | 0.68 | — | — | |
| SCHEMBL7264424 | 0.67 | — | — | |
| SCHEMBL7264422 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | claimed |
| US-20250171438-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-4434584-A2 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2024-09-25 | — | — | EP | disclosed |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| CN-111556871-B | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11634416-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines | H. LUNDBECK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11491140-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-11-08 | — | — | US | disclosed |
| US-8754099-B2 | Oxadiazole beta carboline derivatives as antidiabetic compounds | MERCK SHARP & DOHME CORP (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2523558-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120264777-A1 | OXADIAZOLE BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
| US-20100249410-A1 | PROCESS FOR PREPARING N-ALKYLATED HYDROXYPYRIMIDINONE COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-09-30 | — | — | US | disclosed |
| WO-2010088167-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| US-20080118559-A1 | Pharmaceutical Composition Containing an Anti-Nucleating Agent | MERCK SHARP & DOHME LLC | 2008-05-22 | — | — | US | disclosed |
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | disclosed |